CreatorsPublishersAdvertisers

Frontline Durvalumab/Chemo, With or Without Tremelimumab, Improves PFS in Advanced NSCLC

onclive.com
 2021-09-09

The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial. The first-line combination of durvalumab (Imfinzi) and chemotherapy,...

www.onclive.com

Comments / 0

Comments / 0